

AWARD NUMBER: W81XWH-15-1-0703

TITLE: CXCL14 Blockade of CXCL12/CXCR4 Signaling in Prostate Cancer  
Bone Metastasis

PRINCIPAL INVESTIGATOR: Gregory A. Clines, MD, PhD

CONTRACTING ORGANIZATION: Regents of the University of Michigan  
Ann Arbor, MI 48109

REPORT DATE: December 2018

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                      |                         |                                      | Form Approved<br>OMB No. 0704-0188            |                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------|--------------------------------------|-----------------------------------------------|--------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.                                 |                      |                         |                                      |                                               |                                            |
| 1. REPORT DATE<br>Dec 2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                      | 2. REPORT TYPE<br>Final |                                      | 3. DATES COVERED<br>30 Sep 2015 – 29 Sep 2018 |                                            |
| 4. TITLE AND SUBTITLE<br><br>CXCL14 Blockade of CXCL12/CXCR4 Signaling in Prostate Cancer Bone Metastasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                      |                         |                                      | 5a. CONTRACT NUMBER                           |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         |                                      | 5b. GRANT NUMBER<br>W81XWH-15-1-0703          |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         |                                      | 5c. PROGRAM ELEMENT NUMBER                    |                                            |
| 6. AUTHOR(S)<br>Gregory A. Clines, MD, PhD<br><br>E-Mail: clines@umich.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                      |                         |                                      | 5d. PROJECT NUMBER                            |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         |                                      | 5e. TASK NUMBER                               |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         |                                      | 5f. WORK UNIT NUMBER                          |                                            |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>Regents of the University of Michigan<br>3003 S. State St.<br>Ann Arbor, Michigan 48109-1274                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                      |                         |                                      | 8. PERFORMING ORGANIZATION REPORT NUMBER      |                                            |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                      |                         |                                      | 10. SPONSOR/MONITOR'S ACRONYM(S)              |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         |                                      | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)        |                                            |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                      |                         |                                      |                                               |                                            |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                      |                         |                                      |                                               |                                            |
| 14. ABSTRACT<br>Bone metastasis is a common and unfortunate complication of advanced prostate cancer resulting in significant pain and fractures. The most devastating consequence, however, is that once the cancer has metastasized to bone, the disease is incurable. Up to 90% of men who succumb to prostate cancer have bone metastasis, which demonstrates the strong attraction of prostate cancer to bone. Chemokines are essential in cancer progression and metastasis. The chemokine CXCL14 was identified in a screen for factors that support prostate cancer bone metastasis. In a human prostate cancer tissue microarray, CXCL14 expression was found significantly greater in prostate cancer metastasis to bone compared to metastasis to other organs, suggesting that this chemokine has important effects that are specific to bone. The goal of this proposal is to understand the role of CXCL14 in the homing and progression of prostate cancer to bone. |                      |                         |                                      |                                               |                                            |
| 15. SUBJECT TERMS<br>Prostate cancer, bone metastasis, CXCL14, chemokine signaling, animal models                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                      |                         |                                      |                                               |                                            |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                      |                         | 17. LIMITATION OF ABSTRACT<br><br>UU | 18. NUMBER OF PAGES<br><br>12                 | 19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC |
| a. REPORT<br><br>U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | b. ABSTRACT<br><br>U | c. THIS PAGE<br><br>U   |                                      |                                               | 19b. TELEPHONE NUMBER (include area code)  |

## Table of Contents

|                                                                     | <u>Page</u>  |
|---------------------------------------------------------------------|--------------|
| <b>1. Introduction.....</b>                                         | <b>1</b>     |
| <b>2. Keywords.....</b>                                             | <b>1</b>     |
| <b>3. Accomplishments.....</b>                                      | <b>1-8</b>   |
| <b>4. Impact.....</b>                                               | <b>8</b>     |
| <b>5. Changes/Problems.....</b>                                     | <b>9</b>     |
| <b>6. Products.....</b>                                             | <b>9-10</b>  |
| <b>7. Participants &amp; Other Collaborating Organizations.....</b> | <b>10-11</b> |
| <b>8. Special Reporting Requirements.....</b>                       | <b>11</b>    |
| <b>9. Appendices.....</b>                                           | <b>11-12</b> |

## 1. Introduction

Chemokines play critical roles in cancer progression and metastasis. We identified the chemokine CXCL14 in a screen of factors expressed in prostate cancer bone metastasis. In a human prostate cancer tissue microarray, CXCL14 expression was significantly greater in metastasis to bone compared to soft tissue metastasis, primary prostate tumors and normal prostate. CXCL14 expression was also significantly greater in bone xenografts compared to growth outside the skeleton in animal models of bone metastasis. These data suggest bone-specific actions of prostate cancer and CXCL14. The purpose of this proposal is to understand the role of CXCL14 in the development and progression of prostate cancer bone metastasis.

## 2. Keywords

Prostate cancer, bone metastasis, CXCL14, chemokine signaling, animal models

## 3. Accomplishments

### Major goals:


1. Determine the effects of prostate cancer CXCL14 overexpression to reduce skeletal lesions in an animal model of prostate cancer bone metastasis
2. Determine mechanisms of CXCL14 expression regulation in prostate cancer
3. Determine the cellular effects of CXCL14
  - a. Determine the effects of CXCL14 on  $\beta$ -arrestin 2 recruitment to CXCR4
  - b. Determine the extent to which CXCL14 associates as a dimer with itself and CXCL12
  - c. Determine the effects of CXCL14 on *in vitro* prostate cancer migration and invasion
  - d. Identify novel physical interactions with CXCL14

### Accomplishments

1. Determine the effects of prostate cancer CXCL14 overexpression to reduce skeletal lesions in an animal model of prostate cancer bone metastasis

Using prostate cancer PC-3 cells that overexpress luciferase, we have generated these PC-3 cells to also overexpress CXCL14 or an empty vector control. After intracardiac inoculation, the development of bone and soft tissue lesions was monitored using *in vivo* bioluminescent imaging. The experiment ended 13 weeks after intracardiac inoculation. An example of the same lesion as seen by X-ray and IVIS is shown (**Fig. 1**). Analyses examining for differences in percent of mice with bone lesions by X-ray, percent of mice with bone lesions on X-ray + IVIS imaging, average number of lesions/mice on X-ray, and average number of lesions on X-ray + IVIS imaging was not different (**Fig. 1**).

The conclusion from the data generated suggests that overexpression of CXCL14 does not alter homing of prostate cancer cells to bone and/or expansion of prostate cancer cells in the skeleton.





2. Determine mechanisms of CXCL14 expression regulation in prostate cancer  
As reported in the proposal, we examined CXCL14 protein expression by immunohistochemistry in a comprehensive human prostate cancer tissue microarray (TMA) containing 30 normal prostate samples, 61 primary prostate tumors, 57 soft tissue metastases and 113 bone metastases. CXCL14 expression was significantly

higher in prostate cancer bone metastases compared to soft tissue metastases, primary prostate tumors and normal prostate (**Fig. 2**).

There are a number of possible reasons for increased CXCL14 expression in bone. A hypoxic environment of 1-7% O<sub>2</sub> is created within bone<sup>(1, 2)</sup> that promotes the development of bone metastasis<sup>(3-6)</sup>. Hypoxia induces activation of HIF-1 $\alpha$  signaling that targets genes containing hypoxia response elements.

We examined the effects of hypoxia on CXCL14 expression in the ARCaP<sub>M</sub> prostate cancer cell line. The expression of other genes related to CXCL14 was also examined. CXCL14 expression increased in 1% and 5% O<sub>2</sub> compared to normoxia (21%) (**Fig. 3**). Despite this relative increase in cellular mRNA concentration, the absolute amount of CXCL14 mRNA remained low. The RT-PCR Ct value of CXCL14 in



hypoxia was approximately 28 compared to a Ct value of approximately 15 with the RPL32 housekeeping gene used for normalization.


We next measured CXCL14 protein in conditioned media of the ARCaP<sub>M</sub> and PC-3 prostate cancer cell lines in normoxia and 5% hypoxia. Using an ELISA assay with a sensitivity of ~31 pg/ml, we were unable to detect CXCL14 protein in the conditioned media of the conditions described. Western blots were then performed on cell lysates using a CXCL14 antibody. Unfortunately, the quality of commercial antibodies are poor and were unable to detect CXCL14 in prostate cancer cell lysates.

### 3. Determine the cellular effects of CXCL14

#### a. Determine the effects of CXCL14 on $\beta$ -Arrestin 2 Recruitment to CXCR4

Controversy has existed as to the identity of the CXCL14 receptor. Tanegashima, *et al* reported that a high affinity binding site or sites exists on the human monocytic cell line THP-1 and that knockdown of CXCR4 in this cell line reduced CXCL14 high-affinity binding <sup>(7)</sup>. Moreover, CXCL14 was reported to co-immunoprecipitate with CXCR4. The conclusions of this report were disputed by Otte *et al* that asserted that CXCL14 is not a CXCR4 ligand and that CXCL14 did not modulate CXCL12-mediated CXCR4 receptor phosphorylation, GPCR Ca<sup>2+</sup> signaling, ERK phosphorylation, or CXCL12-mediated CXCR4 receptor internalization <sup>(8)</sup>. In a more recent report, Collins *et al* propose a mechanism in which CXCL14 binds to a CXCR4 homodimer that displaces CXCL12 from the adjacent CXCR4 dimer and effectively downregulates CXCL12 activation of CXCR4 <sup>(9)</sup>.

The availability of tools to adequately study CXCL14 and CXCR4 signaling in prostate cancer has been lacking. We therefore utilized research resources currently available to better understand mechanisms of CXCL14 cellular action. This work was performed in collaboration with Dr. Gary Luker, a collaborator in this proposal. To assess CXCL14-dependent recruitment of  $\beta$ -arrestin 2, the validated MDA-MB-231 click beetle green luciferase complementation reporter system was used to examine mechanisms of CXCL14 signaling <sup>(10-12)</sup>. In this system, the MDA-MB-231 cell line was transduced with fusion proteins CXCR4-CBRN and  $\beta$ -arrestin 2-CBC. Activation of CXCR4 recruits  $\beta$ -arrestin 2 and joins the incomplete luciferase products to generate an active luciferase molecule.



As a control for CXCL14 biologic activity, the transduced MDA-MB-231 cells were treated with CXCL14. A marked increase in AKT phosphorylation at 10 minutes was observed (**Fig. 4A**). Cells that stably expressed the complementation reporters were treated with CXCL14 and CXCL12 individually and combined at concentrations of 60 ng/ml (**Fig. 4B**) and 250 ng/ml (**Fig. 4C**). Cells were serially imaged for up to 120 minutes. Luciferase activity increased rapidly, in a dose-dependent manner, with CXCL12 but not with CXCL14 treatment. Moreover, the addition of CXCL14 to CXCL12 did not lessen the ability of CXCL12 to recruit  $\beta$ -arrestin 2 to CXCR4.

Upon chemokine ligand binding to CXCR4, the CXCR4/ $\beta$ -arrestin 2 complex is internalized resulting in less cell surface receptor available for ligand binding. The availability of surface CXCR4 following CXCL12 treatment was determined using the MDA-MB-231 CXCR4-CBRN/ $\beta$ -arrestin 2-CBC reporter system. The reporter cells

were pretreated with either CXCL12 or CXCL14 in increasing concentrations for one hour followed by a subsequent CXCL12 200 ng/ml treatment at which time luminescence was monitored (**Fig. 4D**). The peak signal was plotted for each chemokine concentration. Pretreatment with increasing concentration of CXCL14 did not alter CXCR4-CBRN/ $\beta$ -arrestin 2-CBC association. However, pretreatment with CXCL12 showed concentration-dependent decreases in further luminescence produced by adding additional CXCL12 that is consistent with receptor internalization and desensitization of signaling. These data suggested that CXCL14 does not promote CXCR4 receptor internalization and that CXCR4 is not a CXCL14 receptor.


b. Determine the extent to which CXCL14 associates as a dimer with itself and CXCL12

CXCL12 exists in both monomeric and dimeric forms at physiologic concentration<sup>(13, 14)</sup>. Each of these CXCL12 species activates CXCR4 but differs in the downstream signaling pathways activated<sup>(14)</sup>. The extent to which CXCL14 exists as a homodimer or heterodimer with other chemokines such as CXCL12 was investigated. A similar complementation strategy as reported above, using the NanoLuc luminescent complementation reporter system, was utilized to examine these interactions. CXCL14, CXCL12, and an irrelevant control protein were cloned in-frame, each receiving adjacent NanoLuc large fragment (LgBit) or the NanoLuc small fragment (SmBit). The combination of the LgBit and SmBit results in a complete and active luminescent protein. HEK-293T cells were co-transfected with various combinations of CXCL14, CXCL12, and the irrelevant protein, followed by luminescent imaging of intact cells and of the conditioned media. This represented a strategy to detect homo- and heterodimer species located within the cellular fraction and in the media. Increased luminescence above what was detected in the chemokine/irrelevant protein combinations was evidence for an interaction.

In the cellular fraction, both CXCL12 and CXCL14 homodimer luminescence was significantly greater than the chemokine/irrelevant heterodimer control indicating the existence of CXCL12 and CXCL14 homodimers (**Fig. 5A**). A CXCL12/CXCL14 heterodimer was also detected, albeit at levels lower than either homodimer. Luminescence was also detected in the conditioned media of cells but at a lower concentration compared to the cell-associated fraction. In the secreted fraction, the luminescence level trended higher for both the CXCL12 and CXCL14 homodimer group but the level was not statistically different compared to the chemokine/irrelevant heterodimer controls. Similarly, the existence of a CXCL12/CXCL14 heterodimer was not detected in the secreted fraction. These data indicate that CXCL12 and CXCL14 homodimers, and a CXCL12/CXCL14 heterodimer exist at higher concentrations within secretory vesicles, but that once secreted from the cell the chemokines revert to monomers.

CXCR4 and CXCR7 (also known as ACKR3) are receptors for CXCL12<sup>(15, 16)</sup>. Using the NanoLuc complementation assay, the physical association of CXCL14 with CXCR4 and CXCR7 was investigated. As expected and previously reported,

CXCL12/CXCR4 and CXCL12/CXCR7 interactions were detected (**Fig. 5B**). However, an interaction between CXCL14 and the two tested chemokine receptors was not detected.



**c. Determine the effects of CXCL14 on *in vitro* prostate cancer migration and invasion**

Three different strategies were employed to determine the effects of CXCL14 to regulate prostate cancer migration and invasion: 1) scratch assays, 2) slide-based chemotaxis assays, and 3) slide-based invasion assays. The strategies were used to test the effects of both CXCL14 overexpression and CXCL14 treatment in the ARCaPM and PC-3 prostate cancer cell lines. We were unable to detect differences with CXCL14 overexpression or treatment on *in vitro* migration or invasion.

**d. Identify novel physical interactions with CXCL14**

Based on our preliminary data and hypothesis that CXCL12 and CXCL14 compete for the same receptor, the new data above suggests that this is not the case. CXCL14 does not compete with CXCL12 to bind with the chemokine receptor

CXCR4. We therefore currently do not know the receptor for CXCL14 or the downstream signaling pathways activated. Instead of assessing competition between CXCL12 and CXCL14, we instead focused on identifying the CXCL14 receptor. This was performed by identifying CXCL14 binding partners using chemical-modifying linkers and mass spectroscopy. The proteins identified (below) belong to the desmosomal complex. It is unclear to us at this time how a chemokine ligand would interact with the desmosome and such interaction has not been reported. However, this is an area of future study.

Keratin, type II cytoskeletal 1  
Keratin, type II cytoskeletal 2 epidermal  
Keratin, type I cytoskeletal 10  
Keratin, type I cytoskeletal 9  
Keratin, type II cytoskeletal 5  
Keratin, type I cytoskeletal 14  
Keratin, type II cytoskeletal 6C  
Keratin, type I cytoskeletal 16  
Keratin, type I cytoskeletal 17  
Keratin, type I cytoskeletal 19  
Keratin, type I cytoskeletal 28

Desmoglein-1  
Desmoplakin  
Junction plakoglobin  
Keratinocyte proline-rich protein  
Vimentin

Actin, cytoplasmic 1  
Actin, cytoplasmic 2

Opportunities for training and professional development  
Nothing to report

Dissemination of results to the communities of interest  
We are currently preparing a manuscript that details much of the negative work reported here. It is however important to contribute to the understanding of CXCL14 with data presented here that CXCR4 is unlikely the receptor for CXCL14.

#### **4. Impact**

Impact on the development of the principal discipline of the project  
1. Our recent results confirm that CXCL14 signaling is more complex than once thought and likely involves an unidentified CXCL14 chemokine receptor cooperating with CXCR4.

2. The original hypothesis that CXCL14 is a CXCL12 inhibitor has been modified so that CXCL14 likely has cooperative actions with CXCL12 in prostate cancer bone metastasis.

Impact on other disciplines

Nothing to report

Impact on technology transfer

Nothing to report

Impact on society beyond science and technology

Nothing to report

## **5. Changes/Problems**

Changes in approach and reasons for change

Based on our preliminary data and hypothesis that CXCL12 and CXCL14 compete for the same receptor, we have new data that this is not the case. CXCL14 does not compete with CXCL12 to bind with the chemokine receptor CXCR4. We therefore currently do not know the receptor for CXCL14 or the downstream signaling pathways activated. Because of this new data, we proposed a change to Task 1b. Instead of assessing competition between CXCL12 and CXCL14, we will instead focus on identifying the CXCL14 receptor. We have already begun this task by identifying CXCL14 binding partners using chemical-modifying linkers and mass spectroscopy. An initial screen identified the desmosomal complex.

Actual or anticipated problems or delays and actions to resolve them

Difficulties in the CXCL14 shRNA lentivirus were encountered. Despite another report of the successful mRNA downregulation of CXCL14 using a similar sequence, we have been unable to demonstrate a significant decline in mRNA concentration after transduction of the CXCL14 shRNA lentivirus in the prostate cancer cell line ARCaP<sub>M</sub>. With the assistance of the University of Michigan Viral Vector Core, we generated an additional four CXCL14 shRNA lentivirus constructs that again were unsuccessful in CXCL14 mRNA knockdown. Because we were unable to identify an shRNA that successfully knocked down CXCL14, we were unable to complete the experiments of Aim 2a.

Changes that had a significant impact on expenditures

Nothing to report

Significant changes in use or care of vertebrate animals

Nothing to report

## **6. Products**

Publications: We are currently preparing a manuscript that details much of the negative work reported here. It is however important to contribute to the understanding of CXCL14 with data presented here that CXCR4 is unlikely the receptor for CXCL14.

## 7. Participants & Other Collaborating Organizations

|                                        |                                                                                                                                              |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Name:                                  | Gregory A. Clines, MD, PhD                                                                                                                   |
| Project Role:                          | PI                                                                                                                                           |
| Researcher Identifier (e.g. ORCID ID): | N/A                                                                                                                                          |
| Nearest person month worked:           | 2.11                                                                                                                                         |
| Contribution to Project:               | Dr. Clines continues to serve as the PI of the projects                                                                                      |
| Funding Support:                       | In addition to the DoD grant, Dr. Clines also receives funding support from the Department of Veteran Affairs and the University of Michigan |

|                                        |                                                                                                                                                     |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Name:                                  | Gary Luker, MD                                                                                                                                      |
| Project Role:                          | Collaborator                                                                                                                                        |
| Researcher Identifier (e.g. ORCID ID): | N/A                                                                                                                                                 |
| Nearest person month worked:           | 0.24                                                                                                                                                |
| Contribution to Project:               | Dr. Luker serves as a collaborator on this project and was instrumental in many of the experimental results as detailed in the attached manuscript. |
| Funding Support:                       | In addition to the DoD grant, Dr. Luker also receives funding support from the NIH and the University of Michigan                                   |

|                                        |                                                     |
|----------------------------------------|-----------------------------------------------------|
| Name:                                  | Katrina Clines, MS                                  |
| Project Role:                          | Lab Manager                                         |
| Researcher Identifier (e.g. ORCID ID): | N/A                                                 |
| Nearest person month worked:           | 4.8                                                 |
| Contribution to Project:               | Ms. Clines serves as the lab manager is responsible |

|                  |                                                                                                               |
|------------------|---------------------------------------------------------------------------------------------------------------|
|                  | for animal handling and performance/supervising most of the experiments                                       |
| Funding Support: | In addition to the DoD grant, Ms. Clines also receives salary support from the Department of Veterans Affairs |

|                                        |                                                                                                     |
|----------------------------------------|-----------------------------------------------------------------------------------------------------|
| Name:                                  | Hyun Sik Moon, BS                                                                                   |
| Project Role:                          | Laboratory Technician                                                                               |
| Researcher Identifier (e.g. ORCID ID): | N/A                                                                                                 |
| Nearest person month worked:           | 9.0                                                                                                 |
| Contribution to Project:               | Mr. Moon has supported and performed many of the experiments in the DoD grant                       |
| Funding Support:                       | In addition to the DoD grant, Mr. Moon also receives salary support from the University of Michigan |

Other organizations  
Nothing to report

## 8. Special Reporting Requirements

Nothing to report

## 9. Appendices

References

## References

1. Grant JL, Smith B. Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man. *Ann Intern Med.* 1963;58:801-9.
2. Hirao M, Hashimoto J, Yamasaki N, et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. *J Bone Miner Metab.* 2007;25(5):266-76.
3. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. *Endocr Relat Cancer.* 2007;14(2):233-44.
4. Mishra A, Wang J, Shiozawa Y, et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. *Mol Cancer Res.* 2012;10(6):703-12.
5. Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. *Nat Rev Urol.* 2013;10(7):405-13.
6. Tong D, Liu Q, Liu G, et al. The HIF/PHF8/AR axis promotes prostate cancer progression. *Oncogenesis.* 2016;5(12):e283.
7. Tanegashima K, Suzuki K, Nakayama Y, et al. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. *FEBS Lett.* 2013;587(12):1731-5.
8. Otte M, Kliever A, Schutz D, Reimann C, Schulz S, Stumm R. CXCL14 is no direct modulator of CXCR4. *FEBS Lett.* 2014;588(24):4769-75.
9. Collins PJ, McCully ML, Martinez-Munoz L, et al. Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4. *FASEB J.* 2017.
10. Coggins NL, Trakimas D, Chang SL, et al. CXCR7 controls competition for recruitment of beta-arrestin 2 in cells expressing both CXCR4 and CXCR7. *PLoS One.* 2014;9(6):e98328.
11. Luker KE, Lewin SA, Mihalko LA, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. *Oncogene.* 2012;31(45):4750-8.
12. Salomonson E, Stacer AC, Ehrlich A, Luker KE, Luker GD. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy. *PLoS One.* 2013;8(1):e51500.
13. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. *Protein Sci.* 2005;14(4):1071-81.
14. Ray P, Lewin SA, Mihalko LA, et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. *Biochem J.* 2012;442(2):433-42.
15. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem.* 2005;280(42):35760-6.
16. Luker KE, Mihalko LA, Schmidt BT, et al. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. *Nat Med.* 2011;18(1):172-7.